Clinical Trials

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors (TACTIC-3 Trial)

Murine models show that TAC101-CLDN18.2 leads to CLDN18.2-specific tumor regression, minimal changes in body weight and low cytokine secretion for reduced toxicity. In the clinic, TAC101-CLDN18.2 will be investigated for the treatment of CLDN18.2-positive solid tumors under the hypothesis of a favorable safety profile and strong efficacy.

Read the Complete Clinical Trial Brief at ClinicalTrials.gov

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors (TACTIC-3 Trial)

Dose Escalation Phase

Indications:
Claudin 18.2+ solid tumors

Status:
Now recruiting

Planned Locations:

  • Dana Farber Cancer Institute in Boston, Massachusetts
  • University of Chicago Comprehensive Cancer Center in Chicago, Illinois
  • MD Anderson Cancer Center in Houston, Texas
  • Roswell Park Comprehensive Cancer Center in Buffalo, New York
  • Memorial Sloan Kettering Cancer Center in New York, New York
  • University of Cincinnati Cancer Center in Cincinnati, Ohio
  • Sidney Kimmel Cancer Center, Thomas Jefferson University in Philadelphia, Pennsylvania
  • Princess Margaret Cancer Center in Toronto, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Quebec, Canada
  • University of Miami in Miami, Florida
  • University of California San Diego in San Diego, California
  • University of Southern California in Los Angeles, California
  • Orlando Health Cancer Center in Orlando, Florida
  • University of Pennsylvania in Philadelphia, Pennsylvania
  • University of Iowa Hospital and Clinics in Iowa City, Iowa
  • VCU Massey Comprehensive Cancer Center in Richmond, Virgina

Dose Expansion Phase

Indication cohorts:
1) CLDN18.2+ gastric and esophageal adenocarcinoma
2) CLDN18.2+ pancreatic ductal adenocarcinoma
3) CLDN18.2+ ovarian and non-small-cell lung cancer

Status:
Recruiting after Phase I dose escalation completion

Planned Locations:

  • Dana Farber Cancer Institute in Boston, Massachusetts
  • University of Chicago Comprehensive Cancer Center in Chicago, Illinois
  • MD Anderson Cancer Center in Houston, Texas
  • Roswell Park Comprehensive Cancer Center in Buffalo, New York
  • Memorial Sloan Kettering Cancer Center in New York, New York
  • University of Cincinnati Cancer Center in Cincinnati, Ohio
  • Sidney Kimmel Cancer Center, Thomas Jefferson University in Philadelphia, Pennsylvania
  • Princess Margaret Cancer Center in Toronto, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Quebec, Canada
  • University of Miami in Miami, Florida
  • University of California San Diego in San Diego, California
  • University of Southern California in Los Angeles, California
  • Orlando Health Cancer Center in Orlando, Florida
  • University of Pennsylvania in Philadelphia, Pennsylvania
  • University of Iowa Hospital and Clinics in Iowa City, Iowa
  • VCU Massey Comprehensive Cancer Center in Richmond, Virgina

Contact us for more information on our trials.